<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The haematological diversity of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) mandates that therapeutic strategies for this disease be guided by an understanding of the disease biology </plain></SENT>
<SENT sid="1" pm="."><plain>Insights into the pathobiology of this disease have given rise to novel treatment strategies which exploit basic biological disturbances </plain></SENT>
<SENT sid="2" pm="."><plain>Myelodysplastic bone marrow progenitors from patients with low <z:mpath ids='MPATH_336'>leukaemia</z:mpath> burden display an accelerated senescence phenotype which is characterised by impaired response to trophic signals and premature apoptotic <z:hpo ids='HP_0011420'>death</z:hpo> of primitive haematopoietic progenitors </plain></SENT>
<SENT sid="3" pm="."><plain>Elaboration of aptogenic cytokines such as TNF-alpha and IL-1beta may reinforce this sequence by up-regulating cellular expression of fas ligand and its cognate receptor, suppressing responsiveness to growth factor stimulation, and accelerating apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Inactivation of p15 or other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor genes antedate disease progression and the emergence of blast populations with reduced capacity for fas mediated cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Herein we review the current understanding of the pathobiology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and promising strategies for therapeutic intervention </plain></SENT>
</text></document>